Abstracts tagged "liver disease"

Abstract Number: 1540 • 2018 ACR/ARHP Annual Meeting
Validation of Hepatic Fibrosis Markers in People with Rheumatoid Arthritis on Methotrexate
Debbie Olsson-White¹, John Olynyk^2,3, Warren Raymond^4,5, Shereen Paramalingam^1,5 and Helen Keen^1,6, ¹Rheumatology, Fiona Stanley Hospital, Murdoch, Australia, ²Gastroenterology and Hepatology, Fiona Stanley Hospital, Murdoch, Australia, ³School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia, ⁴Rheumatology, Sir Charles Gairdner Hospital, Nedlands, Australia, ⁵University of Western Australia, Crawley, Australia, ⁶University of Western Australia, Perth, Australia
Background/Purpose: MTX is the cornerstone of treatment of RA. A relatively rare side effect is liver fibrosis and cirrhosis, the incidence in patients on long-term…
Abstract Number: 2447 • 2018 ACR/ARHP Annual Meeting
Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs
Enrique R Soriano¹, Hugo Madariaga², Oswaldo Castañeda³, Gustavo Citera⁴, Emilce E Schneeberger⁴, Mario H Cardiel⁵, Thijs Hendrikx⁶, Daniela Graham⁷, Harry Shi⁶ and Dario Ponce de Leon⁸, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Clínica del Sur, Arequipa, Peru, ³Clínica Anglo Americana, Lima, Peru, ⁴Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Centro de Investigación Clínica de Morelia, Morelia, Mexico, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Lima, Peru
Background/Purpose: Non-alcoholic fatty liver disease, characterized by hepatic steatosis (HS), is a very common form of chronic liver disease in many countries. Limited data are…
Abstract Number: 1099 • 2017 ACR/ARHP Annual Meeting
Hepatitis B Reactivation in Rheumatologic Patients
Yassir Daghistani¹, Fergus To², Patrick Doyle^3,4, Hin Hin Ko⁵, Mel Krajden^3,4, Jason Kur², Alnoor Ramji⁶, Kam Shojania², Edward Tam⁵, John Wade², Eric Yoshida⁵, Graham Reid², Siegfried Erb⁵ and Mollie Carruthers², ¹Medicine, University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, University of British Columbia, Vancouver, BC, Canada, ³Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada, ⁴BC Centre for Disease Control, Vancouver, BC, Canada, ⁵Gastroenterology, University of British Columbia, Vancouver, BC, Canada, ⁶Gatroenterology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The widespread usage of biologic disease modifying anti-rheumatic drugs (bDMARDs) in rheumatology has increased the risk of hepatitis B virus (HBV) re-activation. The prevalence…
Abstract Number: 1224 • 2017 ACR/ARHP Annual Meeting
BONE Metabolism in LIVER Transplant Patients Two-Year Study. Influence of Medical Intervention PRIOR to Surgery and Antiresorptive Treatment
Eztizen Labrador Sanchez¹, Elena Grau Garcia¹, Karla Arevalo Ruales¹, Jorge Juan Fragio Gil¹, Roxana Gonzalez Mazario¹, Cristina Alcañiz Escandell¹, Ines Canovas Olmos¹, Inmaculada Chalmeta Verdejo¹, Carlos Feced Olmos¹, Luis Gonzalez Puig¹, Jose Ivorra Cortes¹, Isabel Martinez Cordellat¹, Carmen Najera Herranz¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Francisco Miguel Ortiz-Sanjuán¹, Elvira Vicens Bernabeu¹, Victoria Fornes Ferrer², David Hervás Marín², Marta De la Rubia Navarro¹, Angel Moya Herraiz³ and Jose Andres Roman Ivorra¹, ¹Rheumatology Department. Hospital Universitario y Politecnico La Fe, Valencia, Spain, ²Biostatistics Unit. IIS La Fe, Valencia, Spain, ³Hepatology Department. Hospital Universitario y politecnico La Fe, Valencia, Spain
Background/Purpose: Osteoporosis is a frequent complication in patients with chronic liver diseases, mainly in advanced stages or with evidence of cholestasis. During the first few…
Abstract Number: 2380 • 2017 ACR/ARHP Annual Meeting
The Use of Fibroscan in Detecting Early Liver Fibrosis in RA Patients on Long Term MTX with Normal Liver Enzymes
Malack Alachkar¹, T Mathialahan², Sandra Walsh² and Vun Lim³, ¹Rheumatology, The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, ²Gastroenterology, Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board, Wrexham, United Kingdom, ³Rheumatology, Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board, Wrexham, United Kingdom
Background/Purpose: FibroScan (FS) is a non-invasive investigation that allows assessment of possible liver fibrosis by measuring liver stiffness. There are studies which confirm that MTX-related…
Abstract Number: 2522 • 2017 ACR/ARHP Annual Meeting
Metabolic Syndrome, NAFLD and LIVER Stiffness in Psoriatic Arthritis and Psoriasis Patients: A CROSS-Sectional Study
Augusta Ortolan¹, Mariagrazia Lorenzin¹, Giulia Tadiotto¹, Francesca Oliviero¹, Ariela Hoxha¹, Marta Favero², Stefano Piaserico³, Leonardo Punzi¹ and Roberta Ramonda¹, ¹Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ²Rheumatology Unit,Department of Medicine DIMED, University of Padova, Padova, Italy, ³Dermatology Clinic, University of Padova, Padova, Italy
Background/Purpose: Metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD, potentially evolving into liver fibrosis-LF), are more frequent in patient with psoriasis (PsO) with respect…
Abstract Number: 841 • 2015 ACR/ARHP Annual Meeting
Prevalence of Systemic Sclerosis in Primary Biliary Cirrhosis Using the New ACR/EULAR Classification Criteria
Boyang Zheng¹, Catherine Vincent², Marvin J. Fritzler³, Jean-Luc Senécal⁴, Martial Koenig⁵ and France Joyal⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ²Division of Hepatology, Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Department of Medicine, Division of Rheumatology, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁵Department of Medicine, Division of Internal Medicine, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) is a well established disease associated with primary biliary cirrhosis (PBC), however original 1980 American College of Rheumatology (ACR) criteria have…
Abstract Number: 1483 • 2013 ACR/ARHP Annual Meeting
Physician and Patient Characteristics Associated With The Decision To Treat Rheumatoid Arthritis Patients With Biologic Monotherapy In Usual Care Settings
Mariely Nieves-Plaza¹, Heather Eng², Ilinca D. Metes³, Ashwini Shewede⁴, Stephen R. Wisniewski², Ani John⁴ and Marc C. Levesque⁵, ¹Clinical And Translational Science Institute, Univeristy of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Genentech Inc., South San Francisco, CA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: Approximately 30% of rheumatoid arthritis (RA) patients treated with a biologic, receive the biologic as monotherapy i.e. without concomitant oral disease modifying anti-rheumatic drugs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].